# Multiple Target Kinase Inhibitor and Anti-Programmed Death-1 Antibody in Patients With Advanced Thyroid Cancer

> **NCT04521348** · PHASE2 · COMPLETED · sponsor: **Fudan University** · enrollment: 103 (actual)

## Conditions studied

- Thyroid Cancer

## Interventions

- **DRUG:** multiple tyrosine kinase inhibitor(mTKI) Combined with anti-PD-1 antibody

## Key facts

- **NCT ID:** NCT04521348
- **Lead sponsor:** Fudan University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-12-30
- **Primary completion:** 2024-12-31
- **Final completion:** 2024-12-31
- **Target enrollment:** 103 (ACTUAL)
- **Last updated:** 2025-07-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04521348

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04521348, "Multiple Target Kinase Inhibitor and Anti-Programmed Death-1 Antibody in Patients With Advanced Thyroid Cancer". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04521348. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*